A Phase 2 interventional study of JNJ-77242113 and Placebo in Plaque Psoriasis, sponsored by Janssen Research & Development, LLC. Completed at 76 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-13.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Psoriasis by Johnson & Johnson — 3 open to participants now, 12 under way, 7 of them phase 3. Psoriasis · Johnson & Johnson.
Among the 76 studies in Psoriasis by Johnson & Johnson, this one is the 27th largest by enrollment of the 58 interventional ones that give a count, is one of 5 that started in 2022, is one of 12 in phase 2, and was the 61st registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →3 of the 76 studies in Psoriasis by Johnson & Johnson are open now, in 3 countries. Recruiting first, the newest first:
Janssen-Cilag Kft. · Sites in Hungary
Ages 18+
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
Janssen Research & Development, LLC · Sites in Romania
Ages 18+
By country, each count listing its studies:
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 13 · Phase 3 36 · Phase 4 4
First in 2002; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 255 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 222 across the 58 interventional studies, 363 across the 18 observational. Of the 64 that completed or were terminated, 33 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
1 of the studies in Psoriasis by Johnson & Johnson that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07654751Janssen Research & Development, LLCA Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically | 2027-08-31 |
Add it to your calendar (.ics) → With an account.
Among the 76 studies in Psoriasis by Johnson & Johnson, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Th purpose of the study is to evaluate the dose response of JNJ-77242113 in efficacy at Week 16 in participants with moderate-to-severe plaque psoriasis.
The populations of people living with moderate to severe psoriasis is approximately 3.5 billion which are mostly managed with topical and conventional therapies. JNJ-77242113, investigational drug, targets the immune responses in the body and skin which impacts diseases, such as psoriasis and psoriatic arthritis (PsA) and this study evaluates JNJ-77242113 as options of advanced therapies in moderate to severe plaque psoriasis. The total duration of this study is up to 24 weeks which includes a screening period of less than or equal to (\<=) 4 weeks, a 16-week treatment period, and a 4-week safety follow-up period. Safety will be assessed by adverse events (AEs), clinical safety laboratory assessments, electrocardiograms (ECGs), vital signs and physical examinations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will receive JNJ-77242113 Dose 1 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
Drug: JNJ-77242113 · Drug: Placebo
Participants will receive JNJ-77242113 Dose 2 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
Drug: JNJ-77242113 · Drug: Placebo
Participants will receive JNJ-77242113 Dose 3 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
Drug: JNJ-77242113 · Drug: Placebo
Participants will receive JNJ-77242113 Dose 1 BID and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
Drug: JNJ-77242113 · Drug: Placebo
Participants will receive JNJ-77242113 Dose 3 BID and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
Drug: JNJ-77242113 · Drug: Placebo
Participants will receive placebo BID from Week 0 through Week 16.
Drug: Placebo
JNJ-77242113 tablet will be administered orally.
Placebo tablet will be administered orally.
Percentage of Participants Who Achieved at Least 75 Percent (%) Improvement From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 16
Percentage of participants who achieved PASI-75 score (greater than or equal to \[\>=\] 75% improvement from baseline in PASI) at Week 16 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
Time frame: Baseline (Week 0), Week 16
Change From Baseline in PASI Total Score at Week 16
Change from baseline in PASI total score at Week 16 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
Time frame: Baseline (Week 0), Week 16
Percentage of Participants Who Achieved at Least 90% Improvement From Baseline in PASI (PASI-90) at Week 16
Percentage of participants who achieved PASI-90 score (\>=90% improvement from baseline in PASI) at Week 16 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0 = none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
Time frame: Baseline (Week 0), Week 16
Percentage of Participants Who Achieved 100% Improvement From Baseline in PASI (PASI-100) at Week 16
Percentage of participants who achieved PASI-100 score (100% improvement from baseline in PASI) at Week 16 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
Time frame: Baseline (Week 0), Week 16
Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16
The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 millimeters (mm); 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, greater than (\>) 1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 point scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). Higher score indicated more severe disease.
Time frame: At Week 16
Percentage of Participants Who Achieved an IGA Score of Cleared (0) at Week 16
The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 mm; 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, \>1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 point scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). A higher score indicated more severe disease.
Time frame: At Week 16
Change From Baseline in Body Surface Area (BSA) at Week 16
A BSA was commonly used measure of severity of skin disease. It was defined as the percentage of surface area of the body involved with the condition being assessed, (that is, plaque psoriasis). BSA was assessed using hand print method where the surface area of the participant's hand including the palm and all 5 digits was used as a guide to estimate 1% BSA. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
Time frame: Baseline (Week 0) and Week 16
Change From Baseline in Psoriasis Symptoms and Signs Diary (PSSD) Symptoms Scores at Week 16
Change from baseline in PSSD symptoms scores at Week 16 was reported. PSSD was a patient-reported outcome (PRO) questionnaire designed to measure severity of psoriasis symptoms and signs for the assessment of treatment benefit. PSSD was a self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Items were averaged on the daily symptom score when at least 3 items (\>=50 percentage of 5 items) on these scales are answered. The average value was converted into 0-100 scoring, such that symptom score = average value\*10, where, 0= least severe and 100= most severe. Higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
Time frame: Baseline (Week 0) and Week 16
Change From Baseline in PSSD Signs Score at Week 16
Change from baseline in PSSD sign scores at Week 16 was reported. PSSD was a PRO questionnaire designed to measure severity of psoriasis symptoms and signs for assessment of treatment benefit. PSSD was a self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Items were averaged on the daily sign score when at least 3 items (\>=50 percentage of 6 items) on these scales are answered. The average value was converted into 0-100 scoring, such that sign score = average value\*10, where, 0= least severe and 100= most severe. Higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
Time frame: Baseline (Week 0) and Week 16
Percentage of Participants Who Achieved PSSD Symptoms Score Equal to (=) 0 at Week 16 Among Participants With a Baseline Symptoms Score Greater Than or Equal to (>=) 1
The PSSD was a PRO questionnaire designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. PSSD was a self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Items were averaged on the daily symptom score when at least 3 items (\>=50 percentage of 5 items) on these scales are answered. The average value was converted into 0-100 scoring, such that symptom score = average value\*10, where, 0= least severe and 100= most severe. Higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
Time frame: Baseline (Week 0), Week 16
Percentage of Participants Who Achieved PSSD Sign Score = 0 at Week 16 Among Participants With a Baseline Sign Score >=1
The PSSD was a PRO questionnaire designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. PSSD was a self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Items were averaged on the daily sign score when at least 3 items (\>=50 percentage of 6 items) on these scales are answered. The average value was converted into 0-100 scoring, such that sign score = average value\*10, where, 0= least severe and 100= most severe. Higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
Time frame: Baseline (Week 0) , Week 16
Percentage of Participants Who Achieved a Dermatological Life Quality Index (DLQI) of 0 or 1 at Week 16 Among Participants With Baseline DLQI Score Greater Than (>) 1
The DLQI was a dermatology specific health-related quality of life (HRQoL) instrument designed to assess the impact of the disease on a participant's HRQoL. It was a 10-item questionnaire that assesses HRQoL over the past week and in addition to evaluating overall HRQoL, could be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. Each question was scored on a 4-point scale of 0 to 3 (0 = not at all, 1 = a little; 2 = a lot; or 3 = very much, where higher score indicated more impact on QoL). The total score was sum of scores from all 10 questions and it ranged from 0 (not at all) to 30 (very much), with a higher score indicating greater impact on HRQoL. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
Time frame: Baseline (Week 0), Week 16
Change From Baseline in Domain Scores of the Patient-Reported Outcomes Measurement Information System (PROMIS-29) at Week 16
PROMIS-29, 29-item generic HRQoL survey, assesses each 7 PROMIS domains (depression; anxiety; physical function; pain interference; fatigue; sleep disturbance; ability to participate in social roles and activities) with 4 questions and pain intensity. Questions ranked on 5-point Likert Scale (1=never, 2=rarely, 3=sometimes, 4=often and 5=always). Pain intensity was rated on 11-point scale (0=no pain; 10=worst imaginable pain). Higher score= worst pain. Each domain included 4 items, plus a single pain intensity item totaling 29 items. Raw score of each PROMIS domain was converted into a standardized score with mean of 50; standard deviation (SD) of 10 (T-Score). Higher PROMIS T-score=more of concept being measured i.e. higher scores in anxiety, depression, fatigue, pain interference, sleep disturbance= worse symptoms, higher scores in physical function, social roles= better functioning. Baseline: closest measurement taken prior to/at the time of first study drug administration date.
Time frame: Baseline (Week 0) and Week 16
Percentage of Participants Who Achieved at Least a 5-point Improvement From Baseline in Each PROMIS-29 Domain at Week 16
PROMIS-29, 29-item generic HRQoL survey, assesses each 7 PROMIS domains (depression; anxiety; physical function; pain interference; fatigue; sleep disturbance; ability to participate in social roles and activities) with 4 questions and pain intensity. Questions ranked on 5-point Likert Scale (1=never, 2=rarely, 3=sometimes, 4=often, 5=always). Pain intensity was rated on 11-point scale (0=no pain; 10=worst imaginable pain). Higher score=worst pain. Each domain includes 4 items, plus a single pain intensity item totaling 29 items. Raw score of each PROMIS domain was converted into a standardized score with mean of 50; SD of 10 (T-Score). Higher PROMIS T-score= more of the concept being measured i.e. higher scores in anxiety, depression, fatigue, pain interference and sleep disturbance) indicated worse symptoms, higher scores in physical function and social roles= better functioning. Baseline: closest measurement taken prior to/at the time of first study drug administration date.
Time frame: Baseline (Week 0), Week 16
Number of Participants With Treatment-emergent Adverse Event (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
An adverse event (AE) was any untoward medical occurrence in a clinical investigation where participants administered a product or medical device; the event needed not necessarily have a causal relationship with the treatment or usage. A serious adverse event (SAE) was any untoward medical occurrence at any dose that: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or resulted in congenital anomaly/birth defect. TEAE was defined as any event that occurred at or after the initial administration of study agent.
Time frame: From Week 0 through Week 20
| Milestone | Placebo | JNJ-77242113 25 mg QD | JNJ-77242113 50 mg QD | JNJ-77242113 25 mg BID | JNJ-77242113 100 mg QD | JNJ-77242113 100 mg BID |
|---|---|---|---|---|---|---|
| Started | 43 | 43 | 43 | 41 | 43 | 42 |
| Completed | 36 | 36 | 40 | 40 | 41 | 38 |
| Not completed | 7 | 7 | 3 | 1 | 2 | 4 |
| Withdrew: Lost to follow-up | 1 | 3 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 6 | 2 | 3 | 1 | 1 | 2 |
| Withdrew: Other | 0 | 2 | 0 | 0 | 1 | 1 |
Percentage of participants who achieved PASI-75 score (greater than or equal to \[\>=\] 75% improvement from baseline in PASI) at Week 16 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
| Percentage of participants | Placebo | JNJ-77242113 25 mg QD | JNJ-77242113 50 mg QD | JNJ-77242113 25 mg BID | JNJ-77242113 100 mg QD | JNJ-77242113 100 mg BID |
|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieved at Least 75 Percent (%) Improvement From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 16 | 9.3 | 37.2 | 58.1 | 51.2 | 65.1 | 78.6 |
Change from baseline in PASI total score at Week 16 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
| Units on a scale | Placebo | JNJ-77242113 25 mg QD | JNJ-77242113 50 mg QD | JNJ-77242113 25 mg BID | JNJ-77242113 100 mg QD | JNJ-77242113 100 mg BID |
|---|---|---|---|---|---|---|
| Change From Baseline in PASI Total Score at Week 16 | -3.59 ± 9.436 | -12.76 ± 8.050 | -14.56 ± 6.528 | -12.73 ± 8.021 | -13.99 ± 8.653 | -17.44 ± 8.356 |
Percentage of participants who achieved PASI-90 score (\>=90% improvement from baseline in PASI) at Week 16 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0 = none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
| Percentage of participants | Placebo | JNJ-77242113 25 mg QD | JNJ-77242113 50 mg QD | JNJ-77242113 25 mg BID | JNJ-77242113 100 mg QD | JNJ-77242113 100 mg BID |
|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieved at Least 90% Improvement From Baseline in PASI (PASI-90) at Week 16 | 2.3 | 25.6 | 51.2 | 26.8 | 46.5 | 59.5 |
Percentage of participants who achieved PASI-100 score (100% improvement from baseline in PASI) at Week 16 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
| Percentage of participants | Placebo | JNJ-77242113 25 mg QD | JNJ-77242113 50 mg QD | JNJ-77242113 25 mg BID | JNJ-77242113 100 mg QD | JNJ-77242113 100 mg BID |
|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieved 100% Improvement From Baseline in PASI (PASI-100) at Week 16 | 0 | 11.6 | 25.6 | 9.8 | 23.3 | 40.5 |
The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 millimeters (mm); 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, greater than (\>) 1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 point scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). Higher score indicated more severe disease.
| Percentages of participants | Placebo | JNJ-77242113 25 mg QD | JNJ-77242113 50 mg QD | JNJ-77242113 25 mg BID | JNJ-77242113 100 mg QD | JNJ-77242113 100 mg BID |
|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16 | 11.6 | 39.5 | 58.1 | 51.2 | 62.8 | 64.3 |
The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 mm; 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, \>1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 point scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). A higher score indicated more severe disease.
| Percentage of participants | Placebo | JNJ-77242113 25 mg QD | JNJ-77242113 50 mg QD | JNJ-77242113 25 mg BID | JNJ-77242113 100 mg QD | JNJ-77242113 100 mg BID |
|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieved an IGA Score of Cleared (0) at Week 16 | 0 | 16.3 | 34.9 | 14.6 | 27.9 | 45.2 |
A BSA was commonly used measure of severity of skin disease. It was defined as the percentage of surface area of the body involved with the condition being assessed, (that is, plaque psoriasis). BSA was assessed using hand print method where the surface area of the participant's hand including the palm and all 5 digits was used as a guide to estimate 1% BSA. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
| Percentage of BSA | Placebo | JNJ-77242113 25 mg QD | JNJ-77242113 50 mg QD | JNJ-77242113 25 mg BID | JNJ-77242113 100 mg QD | JNJ-77242113 100 mg BID |
|---|---|---|---|---|---|---|
| Change From Baseline in Body Surface Area (BSA) at Week 16 | -2.4 ± 16.51 | -11.9 ± 10.00 | -15.3 ± 11.41 | -13.3 ± 11.08 | -14.6 ± 14.03 | -21.0 ± 13.74 |
Change from baseline in PSSD symptoms scores at Week 16 was reported. PSSD was a patient-reported outcome (PRO) questionnaire designed to measure severity of psoriasis symptoms and signs for the assessment of treatment benefit. PSSD was a self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Items were averaged on the daily symptom score when at least 3 items (\>=50 percentage of 5 items) on these scales are answered. The average value was converted into 0-100 scoring, such that symptom score = average value\*10, where, 0= least severe and 100= most severe. Higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
| Units on a scale | Placebo | JNJ-77242113 25 mg QD | JNJ-77242113 50 mg QD | JNJ-77242113 25 mg BID | JNJ-77242113 100 mg QD | JNJ-77242113 100 mg BID |
|---|---|---|---|---|---|---|
| Change From Baseline in Psoriasis Symptoms and Signs Diary (PSSD) Symptoms Scores at Week 16 | -0.8 ± 29.59 | -35.8 ± 29.22 | -36.7 ± 29.95 | -34.0 ± 29.19 | -29.4 ± 28.28 | -44.0 ± 31.22 |
Change from baseline in PSSD sign scores at Week 16 was reported. PSSD was a PRO questionnaire designed to measure severity of psoriasis symptoms and signs for assessment of treatment benefit. PSSD was a self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Items were averaged on the daily sign score when at least 3 items (\>=50 percentage of 6 items) on these scales are answered. The average value was converted into 0-100 scoring, such that sign score = average value\*10, where, 0= least severe and 100= most severe. Higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
| Units on a scale | Placebo | JNJ-77242113 25 mg QD | JNJ-77242113 50 mg QD | JNJ-77242113 25 mg BID | JNJ-77242113 100 mg QD | JNJ-77242113 100 mg BID |
|---|---|---|---|---|---|---|
| Change From Baseline in PSSD Signs Score at Week 16 | -6.2 ± 22.38 | -38.6 ± 27.55 | -42.7 ± 28.70 | -41.8 ± 27.78 | -41.9 ± 28.65 | -51.1 ± 26.01 |
The PSSD was a PRO questionnaire designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. PSSD was a self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Items were averaged on the daily symptom score when at least 3 items (\>=50 percentage of 5 items) on these scales are answered. The average value was converted into 0-100 scoring, such that symptom score = average value\*10, where, 0= least severe and 100= most severe. Higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
| Percentage of participants | Placebo | JNJ-77242113 25 mg QD | JNJ-77242113 50 mg QD | JNJ-77242113 25 mg BID | JNJ-77242113 100 mg QD | JNJ-77242113 100 mg BID |
|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieved PSSD Symptoms Score Equal to (=) 0 at Week 16 Among Participants With a Baseline Symptoms Score Greater Than or Equal to (>=) 1 | 0 | 16.3 | 23.8 | 17.1 | 27.9 | 26.2 |
The PSSD was a PRO questionnaire designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. PSSD was a self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Items were averaged on the daily sign score when at least 3 items (\>=50 percentage of 6 items) on these scales are answered. The average value was converted into 0-100 scoring, such that sign score = average value\*10, where, 0= least severe and 100= most severe. Higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
| Percentage of participants | Placebo | JNJ-77242113 25 mg QD | JNJ-77242113 50 mg QD | JNJ-77242113 25 mg BID | JNJ-77242113 100 mg QD | JNJ-77242113 100 mg BID |
|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieved PSSD Sign Score = 0 at Week 16 Among Participants With a Baseline Sign Score >=1 | 0 | 2.3 | 14.0 | 9.8 | 16.3 | 14.3 |
The DLQI was a dermatology specific health-related quality of life (HRQoL) instrument designed to assess the impact of the disease on a participant's HRQoL. It was a 10-item questionnaire that assesses HRQoL over the past week and in addition to evaluating overall HRQoL, could be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. Each question was scored on a 4-point scale of 0 to 3 (0 = not at all, 1 = a little; 2 = a lot; or 3 = very much, where higher score indicated more impact on QoL). The total score was sum of scores from all 10 questions and it ranged from 0 (not at all) to 30 (very much), with a higher score indicating greater impact on HRQoL. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
| Percentage of participants | Placebo | JNJ-77242113 25 mg QD | JNJ-77242113 50 mg QD | JNJ-77242113 25 mg BID | JNJ-77242113 100 mg QD | JNJ-77242113 100 mg BID |
|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieved a Dermatological Life Quality Index (DLQI) of 0 or 1 at Week 16 Among Participants With Baseline DLQI Score Greater Than (>) 1 | 2.4 | 27.9 | 37.2 | 30.0 | 55.8 | 43.9 |
PROMIS-29, 29-item generic HRQoL survey, assesses each 7 PROMIS domains (depression; anxiety; physical function; pain interference; fatigue; sleep disturbance; ability to participate in social roles and activities) with 4 questions and pain intensity. Questions ranked on 5-point Likert Scale (1=never, 2=rarely, 3=sometimes, 4=often and 5=always). Pain intensity was rated on 11-point scale (0=no pain; 10=worst imaginable pain). Higher score= worst pain. Each domain included 4 items, plus a single pain intensity item totaling 29 items. Raw score of each PROMIS domain was converted into a standardized score with mean of 50; standard deviation (SD) of 10 (T-Score). Higher PROMIS T-score=more of concept being measured i.e. higher scores in anxiety, depression, fatigue, pain interference, sleep disturbance= worse symptoms, higher scores in physical function, social roles= better functioning. Baseline: closest measurement taken prior to/at the time of first study drug administration date.
| Units on a scale | Placebo | JNJ-77242113 25 mg QD | JNJ-77242113 50 mg QD | JNJ-77242113 25 mg BID | JNJ-77242113 100 mg QD | JNJ-77242113 100 mg BID |
|---|---|---|---|---|---|---|
| Physical Function | -1.04 ± 5.929 | 2.30 ± 6.060 | 5.81 ± 6.896 | 4.55 ± 7.789 | 3.10 ± 7.325 | 5.81 ± 8.408 |
| Anxiety | -2.36 ± 7.971 | -3.98 ± 8.789 | -5.27 ± 8.026 | -5.27 ± 6.787 | -4.70 ± 8.570 | -8.31 ± 9.693 |
| Depression | -1.01 ± 6.238 | -3.09 ± 8.709 | -3.23 ± 6.576 | -1.96 ± 6.569 | -2.62 ± 7.465 | -3.67 ± 8.912 |
| Fatigue | -0.76 ± 5.469 | -2.44 ± 10.983 | -1.50 ± 7.801 | -3.09 ± 8.676 | -2.98 ± 7.818 | -3.75 ± 8.409 |
| Sleep Disturbance | 0.14 ± 6.099 | -1.89 ± 5.859 | -3.45 ± 7.947 | -4.36 ± 6.041 | -1.04 ± 5.995 | -3.19 ± 5.705 |
| Social Roles and Activities | 0.99 ± 8.393 | 4.31 ± 9.035 | 4.82 ± 8.511 | 5.39 ± 10.908 | 5.78 ± 7.538 | 7.73 ± 9.607 |
| Pain Interference | 0.09 ± 7.819 | -6.79 ± 9.038 | -7.41 ± 9.867 | -7.18 ± 7.956 | -3.98 ± 7.889 | -9.56 ± 8.668 |
PROMIS-29, 29-item generic HRQoL survey, assesses each 7 PROMIS domains (depression; anxiety; physical function; pain interference; fatigue; sleep disturbance; ability to participate in social roles and activities) with 4 questions and pain intensity. Questions ranked on 5-point Likert Scale (1=never, 2=rarely, 3=sometimes, 4=often, 5=always). Pain intensity was rated on 11-point scale (0=no pain; 10=worst imaginable pain). Higher score=worst pain. Each domain includes 4 items, plus a single pain intensity item totaling 29 items. Raw score of each PROMIS domain was converted into a standardized score with mean of 50; SD of 10 (T-Score). Higher PROMIS T-score= more of the concept being measured i.e. higher scores in anxiety, depression, fatigue, pain interference and sleep disturbance) indicated worse symptoms, higher scores in physical function and social roles= better functioning. Baseline: closest measurement taken prior to/at the time of first study drug administration date.
| Percentage of participants | Placebo | JNJ-77242113 25 mg QD | JNJ-77242113 50 mg QD | JNJ-77242113 25 mg BID | JNJ-77242113 100 mg QD | JNJ-77242113 100 mg BID |
|---|---|---|---|---|---|---|
| Physical Function | 11.6 | 23.3 | 41.9 | 36.6 | 37.2 | 40.5 |
| Anxiety | 30.2 | 32.6 | 44.2 | 53.7 | 41.9 | 54.8 |
| Depression | 23.3 | 27.9 | 34.9 | 26.8 | 32.6 | 35.7 |
| Fatigue | 18.6 | 20.9 | 23.3 | 41.5 | 25.6 | 42.9 |
| Sleep Disturbance | 16.3 | 23.3 | 32.6 | 43.9 | 23.3 | 38.1 |
| Social Roles and Activities | 23.3 | 30.2 | 46.5 | 56.1 | 44.2 | 57.1 |
| Pain Interference | 20.9 | 46.5 | 55.8 | 51.2 | 41.9 | 64.3 |
An adverse event (AE) was any untoward medical occurrence in a clinical investigation where participants administered a product or medical device; the event needed not necessarily have a causal relationship with the treatment or usage. A serious adverse event (SAE) was any untoward medical occurrence at any dose that: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or resulted in congenital anomaly/birth defect. TEAE was defined as any event that occurred at or after the initial administration of study agent.
| Participants | Placebo | JNJ-77242113 25 mg QD | JNJ-77242113 50 mg QD | JNJ-77242113 25 mg BID | JNJ-77242113 100 mg QD | JNJ-77242113 100 mg BID |
|---|---|---|---|---|---|---|
| TEAEs | 22 | 20 | 26 | 20 | 19 | 26 |
| TESAEs | 0 | 0 | 1 | 0 | 2 | 0 |
Collected over From Week 0 through Week 20. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/43 (0%) | 0/43 (0%) | 10/43 (23.3%) |
| JNJ-77242113 25 mg QD | 0/43 (0%) | 0/43 (0%) | 10/43 (23.3%) |
| JNJ-77242113 50 mg QD | 0/43 (0%) | 1/43 (2.3%) | 15/43 (34.9%) |
| JNJ-77242113 25 mg BID | 0/41 (0%) | 0/41 (0%) | 12/41 (29.3%) |
| JNJ-77242113 100 mg QD | 0/43 (0%) | 2/43 (4.7%) | 8/43 (18.6%) |
| JNJ-77242113 100 mg BID | 0/42 (0%) | 0/42 (0%) | 10/42 (23.8%) |
| Event | Placebo | JNJ-77242113 25 mg QD | JNJ-77242113 50 mg QD | JNJ-77242113 25 mg BID | JNJ-77242113 100 mg QD | JNJ-77242113 100 mg BID |
|---|---|---|---|---|---|---|
| Covid-19Infections and infestations | 0/43 | 0/43 | 0/43 | 0/41 | 1/43 | 0/42 |
| Infected CystInfections and infestations | 0/43 | 0/43 | 1/43 | 0/41 | 0/43 | 0/42 |
| Suicide AttemptPsychiatric disorders | 0/43 | 0/43 | 0/43 | 0/41 | 1/43 | 0/42 |
| Event | Placebo | JNJ-77242113 25 mg QD | JNJ-77242113 50 mg QD | JNJ-77242113 25 mg BID | JNJ-77242113 100 mg QD | JNJ-77242113 100 mg BID |
|---|---|---|---|---|---|---|
| Covid-19Infections and infestations | 5/43 | 5/43 | 3/43 | 8/41 | 2/43 | 4/42 |
| NasopharyngitisInfections and infestations | 2/43 | 1/43 | 8/43 | 3/41 | 1/43 | 2/42 |
| DiarrhoeaGastrointestinal disorders | 1/43 | 2/43 | 4/43 | 2/41 | 1/43 | 1/42 |
| Upper Respiratory Tract InfectionInfections and infestations | 1/43 | 3/43 | 0/43 | 0/41 | 0/43 | 2/42 |
| HeadacheNervous system disorders | 1/43 | 0/43 | 1/43 | 1/41 | 3/43 | 1/42 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/43 | 1/43 | 1/43 | 0/41 | 3/43 | 1/42 |
| Age, Continuous(Years) | Placebo | JNJ-77242113 25 mg QD | JNJ-77242113 50 mg QD | JNJ-77242113 25 mg BID | JNJ-77242113 100 mg QD | JNJ-77242113 100 mg BID | Total |
|---|---|---|---|---|---|---|---|
| Mean | 43.9 ± 14.7 | 44.5 ± 12.72 | 45.1 ± 11.08 | 45.7 ± 11.91 | 44.7 ± 14.11 | 42 ± 11.34 | 44.3 ± 12.65 |
| Sex: Female, Male(Participants) | Placebo | JNJ-77242113 25 mg QD | JNJ-77242113 50 mg QD | JNJ-77242113 25 mg BID | JNJ-77242113 100 mg QD | JNJ-77242113 100 mg BID | Total |
|---|---|---|---|---|---|---|---|
| Female | 18 | 11 | 16 | 11 | 11 | 12 | 79 |
| Male | 25 | 32 | 27 | 30 | 32 | 30 | 176 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | JNJ-77242113 25 mg QD | JNJ-77242113 50 mg QD | JNJ-77242113 25 mg BID | JNJ-77242113 100 mg QD | JNJ-77242113 100 mg BID | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 3 | 4 | 3 | 3 | 2 | 19 |
| Not Hispanic or Latino | 39 | 39 | 38 | 37 | 40 | 40 | 233 |
| Unknown or Not Reported | 0 | 1 | 1 | 1 | 0 | 0 | 3 |
| Race (NIH/OMB)(Participants) | Placebo | JNJ-77242113 25 mg QD | JNJ-77242113 50 mg QD | JNJ-77242113 25 mg BID | JNJ-77242113 100 mg QD | JNJ-77242113 100 mg BID | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 2 | 1 | 1 | 0 | 5 |
| Asian | 5 | 12 | 9 | 7 | 7 | 9 | 49 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 2 | 0 | 0 | 2 |
| Black or African American | 0 | 0 | 0 | 3 | 0 | 2 | 5 |
| White | 37 | 30 | 31 | 27 | 35 | 30 | 190 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 | 1 | 0 | 1 | 4 |
| Region of Enrollment(Participants) | Placebo | JNJ-77242113 25 mg QD | JNJ-77242113 50 mg QD | JNJ-77242113 25 mg BID | JNJ-77242113 100 mg QD | JNJ-77242113 100 mg BID | Total |
|---|---|---|---|---|---|---|---|
| Canada | 7 | 6 | 4 | 7 | 6 | 5 | 35 |
| France | 1 | 1 | 2 | 1 | 1 | 1 | 7 |
| Germany | 8 | 8 | 9 | 7 | 9 | 6 | 47 |
| Japan | 3 | 3 | 3 | 3 | 4 | 4 | 20 |
| Korea, South | 1 | 2 | 3 | 1 | 1 | 3 | 11 |
| Poland | 8 | 9 | 11 | 9 | 13 | 10 | 60 |
| Spain | 2 | 2 | 1 | 2 | 1 | 1 | 9 |
| Taiwan | 1 | 4 | 3 | 3 | 2 | 0 | 13 |
| United Kingdom | 2 | 0 | 0 | 0 | 0 | 1 | 3 |
| United States | 10 | 8 | 7 | 8 | 6 | 11 | 50 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
Ran from Feb 2022 to primary completion in Dec 2022, 10 months.
Results were first posted in Dec 2025, 3 years after primary completion. A results delay was requested in Dec 2023.
Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 10 months is below that.
Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Icotrokinra
Janssen Research & Development, LLC →